Prostalund Ab Stock Short Ratio
PLUN Stock | SEK 8.40 0.60 6.67% |
ProstaLund AB fundamentals help investors to digest information that contributes to ProstaLund's financial success or failures. It also enables traders to predict the movement of ProstaLund Stock. The fundamental analysis module provides a way to measure ProstaLund's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ProstaLund stock.
ProstaLund |
ProstaLund AB Company Short Ratio Analysis
ProstaLund's Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
Competition |
Based on the latest financial disclosure, ProstaLund AB has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and about the same as Medical Care Facilities (which currently averages 0.0) industry. The short ratio for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
ProstaLund Fundamentals
Return On Equity | -0.25 | |||
Return On Asset | -0.13 | |||
Profit Margin | (0.61) % | |||
Operating Margin | (0.59) % | |||
Current Valuation | 215.81 M | |||
Shares Outstanding | 57.19 M | |||
Shares Owned By Insiders | 50.77 % | |||
Shares Owned By Institutions | 1.93 % | |||
Price To Book | 5.09 X | |||
Price To Sales | 13.54 X | |||
Revenue | 17.07 M | |||
Gross Profit | 14.68 M | |||
EBITDA | (7.54 M) | |||
Net Income | (7.88 M) | |||
Cash And Equivalents | 19.11 M | |||
Cash Per Share | 2.98 X | |||
Current Ratio | 6.11 X | |||
Book Value Per Share | 0.79 X | |||
Cash Flow From Operations | (5.8 M) | |||
Earnings Per Share | (0.17) X | |||
Beta | 0.84 | |||
Market Capitalization | 248.19 M | |||
Total Asset | 43.48 M | |||
Retained Earnings | 19 M | |||
Current Asset | 27 M | |||
Current Liabilities | 4 M | |||
Net Asset | 43.48 M |
About ProstaLund Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ProstaLund AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ProstaLund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ProstaLund AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ProstaLund Stock Analysis
When running ProstaLund's price analysis, check to measure ProstaLund's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProstaLund is operating at the current time. Most of ProstaLund's value examination focuses on studying past and present price action to predict the probability of ProstaLund's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProstaLund's price. Additionally, you may evaluate how the addition of ProstaLund to your portfolios can decrease your overall portfolio volatility.